Mirum released Q3 2026 financial results and increased net product sales guidance to $715M-$720M. Additionally, the company received FDA approval for ATEBRIOZ and announced positive trial data for its late-stage pipeline.
Mirum released Q3 2026 financial results and increased net product sales guidance to $715M-$720M. Additionally, the company received FDA approval for ATEBRIOZ and announced positive trial data for its late-stage pipeline.